Biologic Approaches for the Treatment of Partial Tears of the Anterior Cruciate Ligament

Anterior cruciate ligament reconstruction (ACLR) has been established as the gold standard for treatment of complete ruptures of the anterior cruciate ligament (ACL) in active, symptomatic individuals. In contrast, treatment of partial tears of the ACL remains controversial. Biologically augmented ACL-repair techniques are expanding in an attempt to regenerate and improve healing and outcomes of both the native ACL and the reconstructed graft tissue.

PRP in ACL Repairs Jan 2017
By |2018-07-16T17:05:16+00:00July 16th, 2018|Atherosclerosis, Bone Marrow, Platelet Rich Plasma – PRP|Comments Off on Biologic Approaches for the Treatment of Partial Tears of the Anterior Cruciate Ligament

Current Therapeutic Strategies for Stem Cell-Based Cartilage Regeneration

Articular cartilage is a hyaline lining on the articular surface of bone ends. It cushions external impacts and reduces
friction between bones to enable smooth and painless joint motion. Chondrocytes are the only resident cell type in cartilage and comprise 1–5% of articular cartilage. These cells produce collagen, proteoglycans, and hyaluronic acid, which are components of the extracellular matrix (ECM) and underlie the mechanical properties of cartilage.

Stem Cell Based Cartilage Regeneration March 2018
By |2018-07-16T17:03:28+00:00July 16th, 2018|Bone Marrow, Stem Cells|Comments Off on Current Therapeutic Strategies for Stem Cell-Based Cartilage Regeneration

Therapeutic Use of Stem Cells for Myocardial Infarction

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, with acute myocardial infarction (AMI) representing the most common CVD. Coronary artery
disease (CAD) resulting in myocardial infarction (MI) can lead to ischemic heart damage, which, depending on the ability and timing of reperfusion, may be reversible or irreversible. Cardiomyocytes depend on constant delivery of oxygen and nutrients due to the heart’s limited capacity for anaerobic metabolism.

Stem Cells Used in Myocardial Infarction Apr 2018
By |2018-07-16T16:31:12+00:00July 16th, 2018|Bone Marrow, Mesenchymal Stem Cells, Stem Cells|Comments Off on Therapeutic Use of Stem Cells for Myocardial Infarction

Therapeutic Use of Stem Cells for Myocardial Infarction

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, with acute myocardial infarction (AMI) representing the most common CVD. Coronary artery disease (CAD) resulting in myocardial infarction (MI) can lead to ischemic heart damage, which, depending on the ability and timing of reperfusion, may be reversible or irreversible. Cardiomyocytes depend on constant delivery of oxygen and nutrients due to the heart’s limited capacity for anaerobic metabolism.

Stem Cells Used in Myocardial Infarction Apr 2018
By |2018-07-16T16:29:20+00:00July 16th, 2018|Bone Marrow, Mesenchymal Stem Cells, Stem Cells|Comments Off on Therapeutic Use of Stem Cells for Myocardial Infarction